Major Developments in ASX Health and Biotech Firms

2 min read | March 18, 2025 11:00 AM AEDT | By Team Kalkine Media

Major Developments in ASX Health and Biotech Firms — Image source: Shutterstock

Nanosonics Gains FDA Approval for Advanced Sterilising Device

Nanosonics (ASX:NAN) has achieved a significant milestone with the FDA approval of its next-gen sterilising device, Coris, for use in the US market. The device is designed for cleaning flexible endoscopes, enhancing infection control with improved ease of use compared to manual cleaning procedures. This FDA approval marks a crucial step for Nanosonics in expanding its innovative healthcare solutions in the US.

Imricor Medical Systems Secures US$44.1 Million Funding

Imricor Medical Systems (ASX:IMR) has successfully raised US$44.1 million in a placement, propelling the company's growth by enabling the expansion of its commercial operations and supporting its cardiac ablation device. The ablation device, once approved, will offer a safer MRI-guided alternative to x-ray procedures for treating heart arrhythmias, presenting a significant advancement in cardiac care.

PolyNovo Strives for Growth Amidst Management Challenges

PolyNovo (ASX:PNV) is navigating through management challenges as it bids farewell to its CEO, Swami Raote, amid governance reviews. Despite these challenges, PolyNovo remains focused on growth, with strong financial projections. Analyst John Hester of Bell Potter underscores the company's potential for long-term growth, reflecting optimism in its financial performance and governance adjustments.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.